N-Propyl-N'-((4-fluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine | 362519-54-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: N-Propyl-N'-((4-fluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine
• 英文别名: 5-(4-chlorophenyl)-N-(4-fluorophenyl)sulfonyl-4-phenyl-N'-propyl-3,4-dihydropyrazole-2-carboximidamide
• CAS: 362519-54-8
• 化学式: C₂₅H₂₄ClFN₄O₂S
• 分子量: 499.009
• InChiKey: XXYLQSSZLZNJAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  82.5
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
  申请人：Solvay Pharmaceuticals B.V.

  公开号：US20010053788A1

  公开（公告）日：2001-12-20

  The present invention relates, among many things, to novel 4,5-dihydro-1H-pyrazole compounds which can be potent antagonists of the cannabis CB 1 -receptor. The compounds have the formula (I) 1 wherein R and R 1 are the same or different and represent unsubstituted or substituted phenyl, thienyl, or pyridyl, or naphthyl. naphthyl R 2 represents hydrogen, hydroxy, C 1-3 -alkoxy, acetyloxy or propionyloxy, Aa represents one of the groups (i), (ii), (iii), (iv) or (v) as defined herein, Bb represents sulfonyl or carbonyl, and R 3 represents benzyl, phenyl, thienyl or pyridyl, each of which is unsubstituted or substituted, or R 3 represents C 1-8 branched or unbranched alkyl or C 3-8 cycloalkyl, or R 3 represents naphthyl.

  本发明涉及许多方面，其中包括新型4,5-二氢-1H-吡唑烷化合物，可以是大麻CB1受体的有效拮抗剂。这些化合物具有以下式(I)： 其中 R和R1相同或不同，代表未取代或取代的苯基、噻吩基或吡啶基，或者萘基。 R2代表氢、羟基、C1-3-烷氧基、乙酰氧基或丙酰氧基， Aa代表以下定义的(i)、(ii)、(iii)、(iv)或(v)中的一种基团， Bb代表磺酰基或羰基， R3代表苄基、苯基、噻吩基或吡啶基，每种基团可以未取代或取代，或者R3代表C1-8支链或直链烷基或C3-8环烷基，或者R3代表萘基。
• Novel medical uses of 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
  申请人：Antel Jochen

  公开号：US20050080125A1

  公开（公告）日：2005-04-14

  The present invention relates to a novel medical use of 4,5-dihydro-1H-pyrazole compounds which are potent antagonists of the cannabis CB 1 -receptor. Said compounds are particularly suitable in the manufacture of medicaments for the treatment and/or prophylaxis of CB 1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The compounds have the general formula (I) wherein the group Bb represents sulfonyl or carbonyl, and the substituents R, R 1 , R 2 and R 3 , and the group Aa are defined as shown in the description.

  本发明涉及 4,5-二氢-1H-吡唑化合物的一种新型医疗用途，该化合物是大麻 CB 1 的强效拮抗剂。 1 -受体的强效拮抗剂。所述化合物特别适用于制造治疗和/或预防 CB 1 受体相关疾病和/或治疗和/或预防药物引起的青少年肥胖症的药物。这些化合物具有通式 (I) 其中基团 Bb 代表磺酰基或羰基，取代基 R、R 1 , R 2 和 R 3 和 Aa 组的定义如说明所示。
• Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
  申请人：Antel Jochen

  公开号：US20050143441A1

  公开（公告）日：2005-06-30

  The present invention relates to a novel medical use of e.g. 4,5-dihydro-1H-pyrazole compounds which are potent antagonists of the cannabis CB 1 -receptor in combination with lipase inhibitors. Said compounds are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The compounds have the general formula (I) wherein the group Bb represents sulfonyl or carbonyl, and the substituents R, R 1 , R 2 and R 3 , and the group Aa are defined as shown in the description. Preferred lipase inhibitors are orlistat, panclicins, ATL-962 and/or lipstatin.

  本发明涉及 4,5-二氢-1H-吡唑等化合物的新型医疗用途，这些化合物是大麻 CB1-1 的强效拮抗剂。 1 -受体的强效拮抗剂。所述化合物特别适合与脂肪酶抑制剂结合，用于制造治疗和/或预防青少年肥胖症和/或治疗和/或预防药物引起的青少年肥胖症的药物。这些化合物具有通式 (I) 其中基团 Bb 代表磺酰基或羰基，取代基 R、R 1 , R 2 和 R 3 和基团 Aa 的定义如说明所示。优选的脂肪酶抑制剂有奥利司他、泛环素、ATL-962 和/或脂肪司他丁。
• 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB 1-ANTAGONISTIC ACTIVITY
  申请人：Solvay Pharmaceuticals B.V.

  公开号：EP1268435B1

  公开（公告）日：2006-11-22
• 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY
  申请人：Solvay Pharmaceuticals B.V.

  公开号：EP1373216B1

  公开（公告）日：2004-12-15